http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012157471-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 |
| filingDate | 2011-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012157471-A |
| titleOfInvention | CRYSTAL FORMS OF KINASE INHIBITORS |
| abstract | 1. The compound representing N- (4- {4-amino-7- [1- (2-hydroxyethyl) -1H-pyrazol-4-yl] thieno [3,2-c] pyridin-3-yl} phenyl ) -N '- (3-fluorophenyl) urea, in solid crystalline form, where the crystalline form is the free base of Form I and is characterized by at least peaks of X-ray powder diffraction in any one or more of the following positions: 7,20, 8 37, 11.38, 16.75, 16.95, 19.60, 22.04 and 22.86 ° 2θ, ± 0.2 ° 2θ. 2. A compound according to claim 1, wherein the crystalline form is the free base of Form I and is characterized by at least peaks of X-ray powder diffraction at each of these positions. The compound according to claim 1, where the crystalline form is the free base of form I and is characterized by at least peaks of powder x-ray diffraction in each of these positions: 4.36, 7.20, 8.37, 11.38, 14.40 , 14.86, 15.02, 16.75, 16.95, 19.60, 21.66, 22.04, 22.31 and 22.86 ° 2θ, ± 0.2 ° 2θ. 4. The compound according to claim 1, where the crystalline form is a monohydrate. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 and one or more pharmaceutically acceptable excipients. The method of obtaining N- (4- {4-amino-7- [1- (2-hydroxyethyl) -1H-pyrazol-4-yl] thieno [3,2-c] pyridin-3-yl} phenyl) -N ' - (3-fluorophenyl) urea in solid crystalline form, where the crystalline form is the free base of Form I according to any one of claims 1 to 4, including: a) providing a mixture containing N- (4- {4-amino-7- [ 1- (2-hydroxyethyl) -1H-pyrazol-4-yl] thieno [3,2-c] pyridin-3-yl} phenyl) -N '- (3-fluorophenyl) urea, water and tetrahydrofuran, in which N - (4- {4-amino-7- [1- (2-hydroxyethyl) -1H-pyrazol-4-yl] thieno [3,2-c] pyridin-3-yl} phenyl) -N '- (3 -fluorophenyl) urea is completely soluble in the cosolvent; b) causing in the absence of the mixture N- (4- {4-amino-7- [1- (2-gidroksie |
| priorityDate | 2010-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.